## 참고 문헌

1.  Luzar MA, Brown CB, Balf D, Issad B, Monnier B, 등. Exit-site care and exit-site infection in continuous ambulatory peritoneal dialysis (CAPD): results of a randomized multicenter trial. Perit Dial Int 1990; 10(1):25-9.
2.  Herwaldt LA, Boyken LD, Coffman S, Hochstetler L, Flanigan MJ. Sources of Staphylococcus aureus for patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2003; 23(3):237-41.
3.  Lobbedez T, Gardam M, Dedier H, Burdzy D, Chu M, Izatt S, 등. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7years. Nephrol Dial Transplant 2004; 19:3140-3.
4.  Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002; 39(2):337-41.
5.  Annigeri R, Conly J, Vas S, Dedier H, Prakashan KP, Bargman JM, 등. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21(6):554-9.
6.  Piraino B, Bernardini J, Florio T, Fried L. Staphylococcus aureus prophylaxis and trends in gram-negative infections in peritoneal dialysis patients. Perit Dial Int 2003; 23(5):456-9.
7.  Bernardini J, Bender F, Florio T, Sloand J, PalmMontalbano L, Fried L, 등. Randomized double blinded trial of antibiotic exit site cream for the prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16:539-45.
8.  Montenegro J, Saracho R, Aguirre R, Martinez I, Iribar I, Ocharan J. Exit-site care with ciprofloxacin otologic solution prevents polyurethane catheter infection in peritoneal dialysis patients. Perit Dial Int 2000; 20(2):209-14.
9.  Giovanni FM Strippoli, Allison Tong, David W Johnson, Francesco Paolo Schena, Jonathan C Craig. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database of Systematic Reviews 2004, Issue 4, Art. No.: CD004679
10. Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. Mupirocin Study Group. J Am Soc Nephrol 1996; 7(11):2403-8.
11. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Moncalian J, Fernandez-Rivera C, Cao M, 등. Treatment of Staphylococcus aureus nasal carriers in CAPD with mupirocin. Adv Perit Dial 1992; 8:242-5.
12. Bernardini J, Piraino B, Holley JL, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27:695-700.
13. Casey M, Taylor J, Clinard P 등. 2000. Application of mupirocin cream at the catheter exit site reduces exit-site infections and peritonitis in peritoneal dialysis patients. Perit Dial Int 20: 566-68.
14. Thodis E, Bhaskaran S, Pasadakis P 등. 1998. Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int 18: 261-70.
15. Jun Beom Park, Jun Yeung Do, Kyung Woo Yoon 등. The effects of catheter revision and mupirocin on exit site infection/peritonitis in CAPD peritonitis. Korean J Nephrol 2000; 19: 500-508

<PAGE>92
Clinical Practice Guideline for CAPD peritonitis